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INTRODUCTION
There is a high likelihood of mortality in patients with
end stage renal disease (ESRD), who are susceptible to ischemic
heart disease, due to cardiovascular disease more frequently
than ordinary people (1), and approximately 50% of these
patients die from cardiovascular disease (2, 3). Goodman et al.
(4) emphasized the clinical importance of the early detection
of coronary artery atherosclerosis by reporting that calcifica-
tion of the coronary artery in those young patients (approxi-
mately 20-30 yr of age) on dialysis due to ESRD is more
likely to occur than in ordinary people. Moreover, it has been
reported that the severe calcification seen in subjects with
ESRD actually begins long before renal insufficiency is severe
enough to require dialysis (5).
Recently, electron beam computed tomography (EBCT) was
introduced as a method for evaluating the extent of coronary
artery calcification in a non-invasive way (6). The coronary
artery calcium score is the result of a quantitative evaluation
on the calcified area of the coronary artery using EBCT. The
critical condition for obstructive coronary disease is more likely
to increase if the degree of calcification inside the coronary
artery is high (i.e., the calcium score is high) (7). Rumberger
et al. (8) reported that patients with a calcium score >400
by the EBCT calcium score guidelines are very likely (≥90%)
to have at least one “significant’’ coronary artery stenosis.
We undertook this study to determine the prevalence and
extent of coronary-artery calcification in predialysis, hemodial-
ysis, and peritoneal dialysis patients and also to evaluate the
usefulness of EBCT among chronic renal failure (CRF) patients
at risk for cardiovascular diseases. 
MATERIALS AND METHODS
The study involved 81 patients who suffered from CRF,
who were followed up for pre-dialysis receiving conservative
treatment, hemodialysis (HD), or peritoneal dialysis (PD) in
Kyungpook National University Hospital (Daegu, Korea)
from July 2000 to March 2004. The patients were divided
into pre-dialysis (Group I, n=35), HD (Group II, n=31),
and PD groups (Group III, n=15). All subjects gave informed
consent before participation, and the study was approved by
the Ethics Committee of Kyungpook University Hospital.
Screening for coronary-artery calcification was performed
using EBCT. The serum hemoglobin, albumin, blood urea
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Coronary-artery Calcium Scores Using Electron Beam CT in Patients 
with Chronic Renal Failure
We evaluated the risk of coronary-artery disease in patients with chronic renal fail-
ure (CRF) by measuring the coronary-artery calcium scores with electron beam
CT (EBCT). A total of 81 CRF patients were divided into three groups; pre-dialysis
(group I, n=35), hemodialysis (group II, n=31) and peritoneal dialysis (group III, n=15).
The several serum biochemical markers and calcium score levels by EBCT were
determined. The Ca×P products were significantly higher in groups II (p<0.05) and
III (p<0.01) than in group I. The serum calcium levels were significantly higher in
group III than in both group I (p<0.01) and II (p<0.05). The serum calcium level in
15 patients with a calcium score > 400 was significantly higher than the 66 patients
with a score ≤400 (p<0.01). The calcium score was significantly higher in the 15
patients with cardiovascular complications than in the 66 patients without cardiovas-
cular complications (628.9±904.8 vs. 150.4±350.9, p<0.01). EBCT seemed to
be a good diagnostic tool for evaluating the risk of coronary-artery disease ‘‘non-
invasively’’ in CRF patients who are at increased risk of cardiovascular morbidity
and mortality.
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nitrogen (BUN), creatinine (Cr), total cholesterol, calcium
(Ca), phosphorus (P), and parathyroid hormone (PTH) levels
were measured simultaneously. The existence of cardiovas-
cular complications, primary disease of the CRF, the dura-
tion of dialysis, age, and sex were determined. The age and
duration of dialysis were standardized by the termination
point of the EBCT and blood test. The primary diseases of
the CRF with the exception of chronic glomerulonephritis,
diabetes mellitus, and hypertension were classified as “Others’’.
Cases with a history of cerebrovascular accidents, peripheral
vascular disease, and coronary artery disease were classified
as “cardiovascular complications’’.
All imaging procedures were performed using EBCT (C-
150 E.B.T., Imatron, CA, U.S.A.). Contiguous transverse
imaging sections were obtained with using a 3 mm collima-
tion. The images were reconstructed with using a 260 mm
or 300 mm field of view, a matrix of 512 by 512, and a sharp
reconstruction filter. All scans were scored with using spe-
cialized software called “Insight Calcium Plaque Analysis
Program’’ by a skilled physician. According to Agatston et
al. (9), the overall calcium score for each patient was count-
ed by the sum total of the multiplication of the area of coro-
nary artery calcium comprised of at least 4 consecutive pix-
els in more than 130 HU (Hounsfield Unit) CT density, by
the coefficient from 1 to 4, as determined by the peak CT
density of each lesion.
The values are given as mean±SD in case of a normal dis-
tribution or otherwise a median and range. The distribution
of the categorical variables among the groups was assessed
by chi-square analysis. The comparisons among the groups
were made using Mann-Whitney and Kruskal-Wallis tests.
A p value <0.05 was considered as statistically significant.
RESULTS
There were 48 of men and 33 of women whose ages ranged
from 16 to 76 yr with an average age 53. The proportion of
males to females in group I, II and III was 21:14, 20:11 and
7:8, respectively. The mean age was higher in group II than
in groups I and III (57.0±14.0 vs. 51.9±12.0 and 47.9±
11.0 yr, p<0.05). The duration of dialysis was longer in group
III on PD than in group II on HD (31.7±37.0 vs. 13.4±
21.8 months, p<0.05). The primary disease of the CRF in-
cluded 38 cases (47%) of chronic glomerulonephritis followed
by 25 cases (31%) of diabetes mellitus and 12 cases (15%)
of hypertension. The other diseases included 3 cases of poly-
cystic kidney disease, one renal tuberculosis, and 2 unknown
causes. The cardiovascular complications amounted to 15
(19%) out of a total 81 patients, which included 9 coronary
artery disease cases, 5 cerebrovascular accidents and one periph-
eral vascular disease. There were 5 patients with history of
cardiovascular complications in each group (Table 1).
Although the Ca×P product as well as the BUN and Cr
of group II were significantly higher than in group I, there
was no distinctive difference in the calcium score including
the PTH, Ca and P. In a comparison between group I and
III, the Ca and Ca×P product as well as the Cr in group III
were significantly higher than in group I. In a comparison
between group II and III, the serum Ca in group III was sig-
nificantly higher than group II with no significance in the
other parameters. The calcium score in groups I, II and III
Group I (n=35) Group II (n=31) Group III (n=15)
Sex (M/F) 21/14 20/11 7/8
Age (yr) 51.9±12.0 57.0±14.0*
,� 47.9±11.0
Duration of dialysis  - 13.4±21.8 31.7±37.0
�
(month)
Primary disease
CGN 17 11 10
DM 11 10 4
HTN 5 6 1
Others 2 4 0
Cardiovascular 
complication
Present 5 5 5
Absent 30 26 10
Hemoglobin (g/dL) 9.55±2.02 8.98±1.43 9.16±1.78
Albumin (g/dL) 3.97±0.57 3.66±0.71 3.70±0.40*
Total cholesterol  179.3±46.0 174.2±57.4 176.2±44.9
(mg/dL)
BUN (mg/dL) 55.3±23.0 69.8±24.9* 56.1±25.6
Cr (mg/dL) 5.38±2.78 9.28±3.52* 9.68±3.54*
Ca (mg/dL) 8.37±1.19 8.44±1.42 9.37±0.78*
,�
P (mg/dL) 4.48±1.36 5.23±1.63 5.61±1.91
Ca×P (mg
2/dL
2) 236.7±9.4 43.0±12.7* 53.8±17.8*
PTH (pg/mL) 200.3±188.4 231.1±196.2 227.4±177.9
Calcium score 84.6±199.0 211.8±325.5 655.7±1009.8
Table 1. Characteristics of the 81 patients
CGN, chronic glomerulonephritis; DM, diabetes mellitus; HTN, hyper-
tension; Ca×P, serum calcium-phosphorus product; PTH, serum para-
thyroid hormone.
*, p<0.05 vs. Group I; 
� p<0.05 vs. Group II; 
� , p<0.05 vs. Group III.
Group I 
(n=35)
Group II and III 
(n=46)
p value
Hemoglobin (g/dL) 9.55±2.02 9.04±1.54 NS
Albumin (g/dL) 3.97±0.57 3.67±0.62 <0.05
Total cholesterol (mg/dL) 179.3±46.0 174.9±53.1 NS
BUN (mg/dL) 55.3±23.0 65.3±25.7 <0.05
Cr (mg/dL) 5.38±2.78 9.40±3.50 <0.01
Ca (mg/dL) 8.37±1.19 8.74±1.31 NS
P (mg/dL) 4.48±1.36 5.35±1.71 <0.05
Ca×P (mg
2/dL
2) 236.7±9.4 46.6±15.3 <0.01
PTH (pg/mL) 200.3±188.4 229.8±188.1 NS
Calcium score 84.6±199.0 356.6±657.4 NS*
Table 2. Laboratory data according to the presence or absence
of dialysis 
Ca×P, serum calcium-phosphorus product; PTH, serum parathyroid
hormone. *p=0.089.996 C.-D. Kim, J.-H. Cho, H.-J. Choi, et al.
obtained from EBCT was 84.6±199.0 (range, 0 to 903;
median, 4), 211.8±325.5 (range, 0 to 1054; median, 30)
and 655.7±1009.8 (range 0 to 3356; median, 16), respec-
tively, in which group III showed higher results. However,
there was no statistical significance (Table 1).
When a total of 81 patients were divided into a dialysis
(group II and III, n=46) and pre-dialysis group (group I,
n=35), the serum albumin level of the pre-dialysis group
was significantly higher than in the dialysis group (3.97±
0.57 vs. 3.67±0.62 g/dL, p<0.05). The BUN, Cr, P (5.35
±1.71 vs. 4.48±1.36 mg/dL, p<0.05) and Ca×P product
(46.6±15.3 vs. 36.7±9.4 mg2/dL2, p<0.01) of the dialysis
group were significantly higher than in the pre-dialysis group.
However, other biochemical parameters were not significantly
different in both groups. The calcium score of the dialysis
group was 356.6±657.4. This was higher than that in the
pre-dialysis group, which was 84.6±199.0. However, there
was no statistical significance (Table 2).
The P and PTH levels in the patients (n=15) with a calci-
um score >400 and in those (n=66) with a calcium score ≤
400 were not significantly different. However, the Ca×P
product tended to be higher and the serum Ca level was signif-
icantly higher (9.22±0.81 vs. 8.43±1.31 mg/dL, p<0.01)
in the patients with a calcium score >400 than in those with
a calcium score ≤400 (Fig. 1-3).
While the Ca, P, Ca×P product and PTH levels were similar
between the groups with and without cardiovascular complica-
tions (n=15, n=66, respectively), the calcium score of the gro-
up with cardiovascular complications had a significantly higher
level (628.9±904.8 vs. 150.4±350.9, p< 0.01) (Fig. 4).
DISCUSSION
There have been many explanations for the cause of the high
death rate due to cardiovascular disease in patients with CRF
including hypertension, insulin resistance, dyslipidemia, and
hyperhomocysteinemia (10-15). However, such existing risk
factors are unable to explicate the coronary artery atheroscle-
rosis with the accompanying complications. Block et al. (16)
recently asserted that hyperphosphatemia is the risk factor,
which was incurred by a metabolic disorder of Ca and P. The
decrease in renal clearance and nephron, a functional unit of
the kidney, leads to hyperparathyroidism by incurring hyper-
phosphatemia, which causes metastatic calcification on inter-
nal organs such as the myocardium, the liver, lung as well as
the soft tissues, joints, vessels by increasing the Ca×P product
and renal osteodystrophy from the damage to the osseous
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Fig. 1. Serum calcium and phosphorus levels according to coro-
nary-artery calcium score (CACS).
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Fig. 2. Serum calcium-phosphorus product according to coro-
nary-artery calcium score (CACS).
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Fig. 3. Serum parathyroid hormone according to coronary-artery
calcium score (CACS).
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Fig. 4. Distribution of the coronary-artery calcium score (CACS)
level according to presence or absence of cardiovascular com-
plications (CVC).
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tissues. In addition, patients may die of cardiovascular disease
such as a myocardial infarction if the cardiovascular calcifica-
tion inclusive of coronary artery calcification is in progress.
Excessive calcium overload may also be a factor for cardiovas-
cular calcification. Goodman et al. (4) reported that the total
quantity of calcium contained in the phosphate binders taken
into the CRF patients of the group revealing calcification
was twice that of the non-calcification group. PTH also con-
tributes to the risk factors for cardiovascular disease, not only
functioning in increasing the Ca×P product, but also caus-
ing microcalcification by an in-flowing calcium abnormally
into cytoplasm (17, 18).
Magnetic resonance imaging (MRI), conventional CT, heli-
cal CT, and intravascular ultrasonography have been used to
evaluate coronary artery calcification. However, calcification
measurements on the coronary artery through EBCT are be-
coming popular. The major feature of EBCT is that it is opti-
mized for visualizing especially the coronary artery in a high
temporal resolution between 50-100 msec and in a high spa-
tial resolution less than 0.5 mm2 (19). In addition, it enables
a quantitative evaluation of coronary-artery calcification, man-
ifested in the so called “calcium score’’, by sensitively and
rapidly detecting the calcified lesion of all the coronary artery
areas without using contrast media. Agatston et al. (9) proved
that EBCT was excellent quantitative evaluation diagnostic
methodology for investigating coronary artery calcification.
The American Heart Association has acknowledged the valid-
ity of EBCT for detecting coronary artery calcification, where
the detection of coronary artery calcification through EBCT
provides the corroborative confirmation of the existence of
atherosclerotic plaque in the coronary arteries. Furthermore,
an increase in calcification increases the risk of obstructive
coronary disease (7).
Although the major reason for the death of CRF patients
is cardiovascular disease, it has been thought of as being the
case only for the older ESRD patients on dialysis. However,
Braun et al. (20) reported that the frequency of coronary artery
calcification in the patients with ESRD on HD is larger than
in age and gender matched non-dialysis patients with docu-
mented or suspected coronary artery disease and Merjanian
et al. (5) reported that nondialyzed individuals with diabetic
renal disease have a significantly greater prevalence and severity
of vascular and valvular calcification compared to matched
nondiabetic controls with normal renal function. Coronary
and aortic wall calcification is significantly greater among
individuals with diabetic renal disease, when compared to
normoalbuminuric diabetics. This demonstrates that the severe
calcification seen in subjects with ESRD actually begins long
before renal insufficiency is severe enough to require dialysis.
Goodman et al. (4) examined coronary artery calcification
using EBCT on 39 patients with renal failure under dialysis
and 60 normal controls, and performed a comparative anal-
ysis on the clinical characteristics and chemical tests on the
serum Ca and P level. They reported that 14 out of 16 patients
with CRF had calcification in their coronary arteries. In con-
trast, only 3 of the 60 in the control group had calcification.
The group found to have calcification was generally older
with a longer dialysis term than the non-calcification group,
and the serum P, Ca×P product were also higher. In addi-
tion, 10 patients who had calcification in progress underwent
EBCT again after an average 20±3 months follow-up. The
results showed that the calcium score had increased approxi-
mately two times compared to the previous result. Moreover,
Eifinger et al. (21) measured the extent of coronary artery calci-
fication, using EBCT on a total of 16 asymptomatic patients
ranging from 14 to 39 yr of age under renal replacement
therapy. Of these, 6 patients were found to have calcification,
which emphasized that the early detection of coronary artery
calcification is one of the ways to prevent the cardiovascular
complications and ultimately to decrease the death rate.
It might be suspected that continuous ambulatory peri-
toneal dialysis (CAPD) would present fewer problems with
respect to renal osteodystrophy than HD does, because CAPD
provides more consistent steady-state biochemical control
and permits a less restrictive diet. However, the influence
that the mode of dialysis has on the calcium and phospho-
rus metabolism of patients with renal disease is controver-
sial. So, to determine the influence of the mode of dialysis
on the cardiovascular system and calcium metabolism, our
study performed the comparison by dividing the CRF patients
into three groups, “Pre-dialysis’’ (group I, n=35), “HD’’ (group
II, n=31), and “PD’’ (group III, n=15) without setting a con-
trol group and limiting the age, the duration of dialysis, and
the existence of symptoms. One study (22) reported that no
significant differences were seen in serum levels of calcium,
phosphorus, and PTH between patients on CAPD and patients
on HD. However, in our study, the serum Ca level of the PD
group was significantly higher than the pre-dialysis and HD
groups and the Ca×P product of the PD group tended to be
higher than the HD group. In addition, when the pre-dial-
ysis group was compared to the HD and PD groups together
as a dialysis group, serum P level and the Ca×P product of
the dialysis group was significantly higher than in the pre-
dialysis group and the calcium score of the dialysis group
(356.6±657.4) was higher than that in the pre-dialysis group
(84.6±199.0) but there was no statistical significance. While
there was a tendency for the calcium score of the PD group
to be higher than the pre-dialysis and HD group, there was
no statistical significance, which was attributed to the small
sample size of the PD group. Despite the fact that the patients
in the PD group had a tendency to be younger than the pre-
dialysis and HD group, the calcium score of the PD group
was higher than in the pre-dialysis and HD. It is believed
that Ca, P and the Ca×P product should be controlled more
strictly in the PD group than in the other groups.
Rumberger et al. (8) suggested the so-called “EBCT cal-
cium score guidelines’’ in order to apply the calcium score
obtained from the EBCT to clinical practice. These guide-998 C.-D. Kim, J.-H. Cho, H.-J. Choi, et al.
lines recommend an examination on ischemic heart disease
through a pharmacological or exercise stress test together
with a revision of the risk factors for those whose calcium
score >400 because the risk of coronary artery disease increases
up to 90% in these patients. In our study, when 66 patients
with a calcium score ≤400 were compared to the 15 patients
with a score >400, the group with a calcium score >400 had
a significantly higher serum calcium level and tended to be
higher the Ca×P product than the group with a calcium
score ≤400. In addition, in a comparison between the 15
patients with cardiovascular complications and the 66 patients
without such complications, the calcium score was signifi-
cantly higher in those with cardiovascular complications.
Our results agree with the previous evidences that arterial
calcification has been linked to an elevated Ca×P product
(20), and increased myocardial calcium content and vascular
calcifications in dialysis patients were shown to have a strong
positive correlation with an elevated Ca×P product and
inverse correlation with left ventricular function (23). It has
been known that elevated Ca×P product may contribute
to the high mortality and morbidity of patients with end-
stage renal disease. Moreover, it is certainly conceivable that
vascular and cardiac calcification in particular leads to com-
plications and increased mortality. In conclusion, this study
suggests that EBCT seemed to be a good diagnostic tool for
evaluating the risk of coronary-artery disease “non-invasive-
ly’’ in CRF patients who are at increased risk of cardiovascu-
lar morbidity and mortality.
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